These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 19912209

  • 1. Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model.
    Jankun J, Selman SH, Keck RW, Łysiak-Szydłowska W, Skrzypczak-Jankun E.
    BJU Int; 2010 May; 105(10):1469-76. PubMed ID: 19912209
    [Abstract] [Full Text] [Related]

  • 2. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ, Greenfield RS.
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [Abstract] [Full Text] [Related]

  • 3. Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss.
    Jankun J, Keck R, Selman SH, Skrzypczak-Jankun E.
    Int J Mol Med; 2010 Oct; 26(4):501-4. PubMed ID: 20818488
    [Abstract] [Full Text] [Related]

  • 4. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
    Jankun J, Aleem AM, Selman SH, Basrur V, Skrzypczak-Jankun E.
    Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
    [Abstract] [Full Text] [Related]

  • 5. Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.
    Shahrour K, Keck R, Jankun J.
    Biomed Res Int; 2015 Jan; 2015():392862. PubMed ID: 25883959
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Plasminogen activator inhibitor with very long half-life (VLHL PAI-1) can reduce bleeding in PAI-1-deficient patients.
    Jankun J, Skrzypczak-Jankun E.
    Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):144-50. PubMed ID: 23988002
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
    Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A.
    Thromb Haemost; 1990 Feb 19; 63(1):82-6. PubMed ID: 2111051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.